The manufacturer reported 95% efficacy in its mRNA-based jab, when measured from 28 days after participants received the first injection. COVAX is an initiative run by the vaccine alliance, GAVI, that aims to ensure equitable access to a Covid vaccine when it becomes available. The analysis looked at how much protection the vaccine could offer from two weeks after participants received the second injection. The dosage regimen where participants received half a dose followed by a full dose one month later, showed 90% efficacy. The jab gained notoriety as the first registered Covid vaccine in Russia, before phase three clinical trials had concluded.

Source: News 24 December 08, 2020 04:02 UTC